F10 and deep vein thrombosis: Over the past several years, many direct oral anticoagulant agents like anti-factor Xa inhibitors (such as apixaban, edoxaban, rivaroxaban) and factor II inhibitors such as dabigatran and others have come into prominence and have been approved and being utilized for several indications like stroke prophylaxis in atrial fibrillation, DVT prophylaxis in orthopedic surgical patients to the treatment of patients with thromboembolic conditions like deep vein thrombosis and pulmonary embolism [18].